Exchange & Returns Information
Review Details
(0)
| Generic For | FEMARA |
|---|---|
| Active Ingredient | LETROZOLE |
| Strength | 2.5MG |
| Manufacturer | ARISTO PHARMACEUTICALS PVT LTD |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 2 BOXES - 100 TABLETS | $ 0.36 | $ 35.90 |
$ 30.52
Apply ZARVY26 (-15%)
You save $ 5.39
|
||
| 3 BOXES - 150 TABLETS | $ 0.44 | $ 66.40 |
$ 56.44
Apply ZARVY26 (-15%)
You save $ 9.96
|
||
| ★ Best Value 6 BOXES - 300 TABLETS | $ 0.33 |
8% $ 107.70
$ 99.60
|
$ 84.66
Apply ZARVY26 (-15%)
You save $ 14.94
|
Reference information will be available soon.
Letpro 2.5 is a generic formulation of letrozole 2.5mg, a potent non-steroidal aromatase inhibitor designed to suppress estrogen synthesis by blocking the aromatase enzyme responsible for converting androgens into estrogens. It is a frontline endocrine therapy in postmenopausal women with hormone receptor-positive (HR+), HER2-negative breast cancer and is indicated across all stages—from early adjuvant to advanced metastatic disease. Letrozole plays a critical role in long-term recurrence prevention strategies and is often prescribed for up to 10 years in high-risk patients. In recent years, it has also gained traction as an ovulation induction agent in women with infertility related to anovulation or polycystic ovarian syndrome (PCOS), broadening its application within FEMTECH.
AntiCancer Drugs > HR+ Breast Cancer in Postmenopausal Women
Approved for adjuvant, neoadjuvant, and metastatic endocrine therapy in hormone receptor-positive breast cancer. Letrozole reduces systemic estrogen levels, depriving estrogen-dependent tumors of their growth stimulus.
AntiCancer Drugs > Advanced or Metastatic Breast Cancer
Combined with CDK4/6 inhibitors (e.g., ribociclib, palbociclib) or fulvestrant, Letpro 2.5 forms part of the first-line therapeutic regimen for patients with advanced HR+/HER2- disease. Its mechanism complements these agents to significantly improve progression-free survival.
FEMTECH > Ovulation Induction for Infertility
Used off-label as an effective ovulation induction agent in anovulatory women, especially those with PCOS. Letrozole promotes follicular development by enhancing FSH secretion through estrogen suppression, thereby improving ovulation and pregnancy rates.
Letrozole selectively inhibits the aromatase enzyme in adipose and peripheral tissues, reducing estrogen production in postmenopausal women. Estrogen is a primary driver of tumor proliferation in HR+ breast cancer, and by decreasing its levels, letrozole provides a powerful antiproliferative effect. It does not affect adrenal steroidogenesis and offers a favorable safety profile for long-term administration. In fertility treatments, it stimulates ovulation by releasing the hypothalamic-pituitary axis from estrogen-mediated negative feedback. Its dual utility in oncology and reproductive health highlights its pharmacological versatility.
Standard Dose for Breast Cancer:
→ Letrozole: 2.5 mg orally once daily
→ Taken continuously throughout the 28-day cycle without breaks
→ May be prescribed for up to 10 years in early-stage patients depending on recurrence risk
→ Suitable for monotherapy or in combination with other endocrine agents
Combination with Ribociclib:
→ Ribociclib: 600 mg orally once daily for 21 days followed by 7 days off (28-day cycle)
→ Letrozole: 2.5 mg orally once daily without break throughout the same cycle
→ Applies to both pre/perimenopausal and postmenopausal women when ovarian suppression is included
Ovulation Induction (Off-label use):
→ Commonly 2.5–5 mg once daily for 5 consecutive days starting on cycle day 3 or 5
→ Dose may be increased or repeated in subsequent cycles depending on response
→ Close monitoring of follicular development via ultrasound is recommended
Administration Guidelines:
→ Take at the same time daily, with or without meals
→ If a dose is missed, take as soon as remembered unless close to the next scheduled dose. Do not double up
→ Regular bone density assessments and lipid profile monitoring are advised during long-term use
Store at a temperature not exceeding 25°C in a dry place
Protect from moisture and direct sunlight
Keep tablets in the original blister until administration
Ensure the product is kept out of reach of children
Properly discard after expiry
Common: hot flashes, arthralgia, fatigue, nausea, dizziness
Less common: elevated cholesterol, osteoporosis, headache, insomnia
Rare: bone fractures, hepatotoxicity, thromboembolic events
Seek immediate medical advice if experiencing signs of jaundice, sudden chest pain, or vision changes.
No reviews yet. Be the first to review this product!
No combo deals available at the moment.
